The Pathophysiology and Pharmacological Treatment of Huntington DiseaseReportar como inadecuado




The Pathophysiology and Pharmacological Treatment of Huntington Disease - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Behavioural Neurology - Volume 26 2013, Issue 4, Pages 245-253

The Michael Trimble Neuropsychiatry Research Group, Department of Neuropsychiatry, BSMHFT and University of Birmingham, Birmingham, UK

Received 22 May 2012; Accepted 22 May 2012

Copyright © 2013 Hindawi Publishing Corporation and the authors. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Introduction: Huntington disease HD is a progressive neurodegenerative condition characterised by motor, cognitive and behavioural dysfunction, and has an autosomal dominant mode of inheritance. As there is currently no treatment to delay progression of the disease, pharmacological intervention is aimed at symptomatic relief.

Methods: We set out to assess the current evidence on the pharmacological treatment of motor and non-motor symptoms in HD by carrying out a systematic literature review across five large scientific databases.

Results: The search generated 23 original studies meeting our search criteria. Studies on the following drug classes were obtained: dopamine DA depleting agents, neuroleptics, anti-glutamatergic agents, acetylcholinesterase inhibitors, GABA agonists, cannabinoids, antidepressants and potential neuroprotective agents. Tetrabenazine TBZ, a DA depleting agent, was the only pharmacotherapy shown to have a clinically meaningful, statistically significant effect on chorea. The majority of the reviewed studies focussed on the treatment of motor symptoms of HD.

Discussion: Overall, the evidence base for the pharmacological management of HD is poor. There is a clear need for future high quality randomised controlled trials on the symptomatic treatment of HD, particularly on the pharmacotherapy of non-motor symptoms of HD.





Autor: Connie Pidgeon and Hugh Rickards

Fuente: https://www.hindawi.com/



DESCARGAR PDF




Documentos relacionados